OBJECTIVES: To evaluate the quality of Chinese pharmacoeconomic evaluation literatures published between 2012 to 2014 retrieved from the Chinese National Knowledge Infrastructure (CNKI) to assess their adherence to the recommendations of the Chinese Pharmacoeconomic Guidelines. METHODS: Identified literature was screened according to pre-specifc criteria to access legibility for inclusion. Each included literature was systematically compared against the recommendations proposed by the Chinese guideline. The level of adherence was expressed descriptively as percentage. RESULTS: After culling, 259 literatures were included in the comparative analysis. When compared to a previous study evaluating the quality of similar literature published between 1997 and 2007, our results showed improvements in certain technical aspects over the years. Particularly, the improvement was seen in more diverse evaluation methods being used, increased use of cost-utility analysis (2.43% in 2012-2014 vs. 0.26% in 1997-2007) and use of discounting (45.00% in 2012-2014 vs. 4.35% in 1997- 2007). In addition, small number of studies were starting to apply modelling. CONCLUSIONS: The quality of economic evaluation literature had improved in recent years, with more researchers realizing the importance and necessity of using discounting, sensitivity analysis and modeling when conducting economic evaluation. Our study also highlights certain important areas when conducting economic evaluation needing further attention in China. These include the ICER threshold of economic analysis, more detailed guidance in performing sensitivity analysis and modelling as well as transferability of cost data across different regions. Overall, our results would support the positive contributing role of the Chinese Economic Guideline in promoting economic evaluation in China.